Loading stock data…
ANTX
$4.68+0.13 (+2.86%)
Market ClosedLast close May 1
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AN2 Therapeutics, Inc. in the Healthcare sector is trading at $4.68. The stock is currently 32% below its 52-week high of $6.91, remaining 172.1% above its 200-day moving average. Technical signals show overbought RSI of 84 and bullish MACD crossover, explaining why ANTX maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 84) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.68
Potential Upside
5%
Whystock Fair Value$4.91
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for pa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$143.80M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-1.32
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-66.29%
Volume
Today's trading volume
106,567
Recent News
AN2 Therapeutics (ANTX) Upgraded to Buy: What Does It Mean for the Stock?
AN2 Therapeutics (ANTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Medical Stocks Lagging Allogene Therapeutics (ALLO) This Year?
Here is how Allogene Therapeutics (ALLO) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Positive Signs As Multiple Insiders Buy AN2 Therapeutics Stock
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...